Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study-Reference-Cited by-同舟云学术

Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Published:2022-03 Issue:10 Volume:18 Page:1235-1244
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Yasin Ayse Irem¹^ORCID,Aydin Sabin Göktas²^ORCID,Sümbül Bilge³,Koral Lokman⁴,Şimşek Melih¹^ORCID,Geredeli Çağlayan⁵,Öztürk Akın⁶,Perkin Perihan⁷,Demirtaş Derya⁸,Erdemoglu Engin⁹,Hacıbekiroglu İlhan¹⁰,Çakır Emre¹⁰,Tanrıkulu Eda¹¹,Çoban Ezgi¹¹,Ozcelik Melike¹²,Çelik Sinemis¹³,Teker Fatih¹⁴,Aksoy Asude¹⁵,Fırat Sedat T¹⁶,Tekin Ömer¹⁷,Kalkan Ziya¹⁸,Türken Orhan¹⁹,Oven Bala B²⁰,Dane Faysal²¹,Bilici Ahmet²,Isıkdogan Abdurrahman¹⁸,Seker Mesut¹,Türk Hacı M¹,Gümüş Mahmut⁹

Affiliation:

1. Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey

2. Medipol University, Department of Medical Oncology, Istanbul 34214, Turkey

3. Bezmialem Vakif University, Department of Microbiology, Istanbul 34093, Turkey

4. Canakkale 18 March University, Department of Medical Oncology, Canakkale 17020 ,Turkey

5. Okmeydani Training and Research Hospital, Department of Medical Oncology, Istanbul 34384, Turkey

6. SureyyapasaChest Dıseases And Thoracıc Surgery Traınıng And Research Hospıtal, Department of Medical Oncology, Istanbul 34844, Turkey

7. Yildirim Beyazit University Yenimahalle Training and Research Hospital, Department of Medical Oncology, Ankara 06330, Turkey

8. AnkaraCity Hospital, Department of Medical Oncology, Ankara06800, Turkey

9. GöztepeMedeniyet University, Department of Medical Oncology, Istanbul 34000, Turkey

10. Sakarya University Medicine Faculty, Departmentof Medical Oncology, Sakarya 54050, Turkey

11. Haydarpasa Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkey

12. Marmara University School of Medicine, Department of Medical Oncology, Istanbul 34722, Turkey

13. Istanbul Oncology Hospital, Department of Medical Oncology, Istanbul 34846, Turkey

14. Gaziantep University, Department of Medical Oncology, Gaziantep 27470, Turkey

15. Fırat University Faculty of Medicine, Department of Medical Oncology, Elazıg 23119, Turkey

16. Erciyes University, Department of Medical Oncology, Kayseri 38039, Turkey

17. InönüUniversity, Department of Medical Oncology, Malatya 44280, Turkey

18. DicleUniversity, Department of Medical Oncology, Diyarbakır 21200, Turkey

19. MaltepeUniversity, Department of Medical Oncology, Istanbul 34844, Turkey

20. Bahcesehir University School of Medicine, Department of Medical Oncology, Istanbul 34349, Turkey

21. Acıbadem University, Department of MedicalOncology, Istanbul 34758, Turkey

Abstract

Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov)

Funder

Oncological Clinical Research Association

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-1248

Reference29 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. Immune Responses to SARS-CoV-2 Among Patients With Cancer

3. WHO. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/region/euro/country/tr